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Background: Using a double-blinded randomized crossover design, this study aimed to evaluate acute postop-
erative pain management, swelling and trismus in 46 volunteers undergoing extractions of the two lower third 
molars, in similar positions, at two different appointments who consumed a tablet of either NE (naproxen 500 mg 
+ esomepraz ole 20 mg) or only naproxen (500 mg) every 12 hours for 4 days.
Material and Methods: Parameters were analyzed: self-reported pain intensity using a visual analog scale (VAS) 
pre- and postoperative mouth opening; incidence, type and severity of adverse reactions; total quantity consumed 
of rescue medication; and pre- and postoperative swelling.
Results: Female volunteers reported significantly more postoperative pain at 1, 1.5, 2, 3 and 4hrs after surgery 
while also taking their first rescue medication at a time significantly earlier when consuming NE when compared 
to naproxen (3.7hrs and 6.7hrs). Conversely, no differences were found between each drug group in males. 
Conclusions: In conclusion, throughout the entire study, pain was mild after using either drug in both men and 
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women with pain scores on average well below 40mm (VAS), although in women naproxen improved acute postop-
erative pain management when compared to NE.
Key words: Oral surgery, third molar, pain, naproxen, esomeprazole, NSAIDs.  
Introduction
Third molar extraction is the most common surgical pro-
cedure in dentistry, and it is commonly used to inves-
tigate acute postoperative pain and inflammation (1). In 
particular, third molar surgery involves the manipulation 
of the molar and the surrounding soft tissue and bone. 
The manipulation of the surrounding loose connective 
mediates the release of inflammatory agents leading to 
edema, trismus and pain (1,2-4). After third molar ex-
traction, postoperative pain is generally reported to be 
short term with mild intensity, followed by greater pain 
intensity 2 to 4 hours after surgery with many patients re-
quiring analgesic medication (4,5). Swelling and trismus 
are frequent manifestations associated with the inflam-
matory process originating from oral surgeries (1-4).
Nonsteroidal anti-inflammatory drugs (NSAIDs) have 
been extensively used to reduce these postoperative 
complications resulting from third molar surgeries 
(2-4,6), and are commonly prescribed for the control of 
chronic and acute inflammatory pain conditions (3,7,8). 
The therapeutic effects of NSAIDs are mediated by 
inhibiting cyclooxygenases (COXs). The two isoforms 
of COXs, COX-1 and COX-2, play important roles in 
inflammation, pain, and fever via the production of 
prostaglandins (PGs) and thromboxanes (9). Different 
types of NSAIDs may non selectively inhibit both 
COX-1 and COX-2, or selectively inhibit COX-2. In 
particular, selective NSAIDs that affect COX-1 more 
so than COX-2 have anti-inflammatory, analgesic 
and antipyretic effects, but they also often lead to 
gastrointestinal problems associated with COX-1 
inhibition. Moreover, these gastric problems can lead to 
significant pain independent of the original condition.
It should also be noted that, when compared to men, 
women have increased pain somatization, sensitivity 
and intolerance for various types of pain (10). Further-
more, some pain symptoms have been demonstrated to 
fluctuate with the menstrual cycle (11,12) although fur-
ther investigations are needed. When examining renal 
hemodynamic parameters Cherney et al. (13) (2008) 
found that women were significantly sensitive to COX-2 
inhibition whereas men were not, and they hypothesized 
that women might have greater baseline prostaglandin 
activity when compared to men. They also hypothesized 
that vasodilatory prostaglandins are more effective in 
women versus men (13). In animal models, others have 
implicated estrogen as a mediating factor since estrogen 
increased vasodilatory prostaglandin synthesis (14-16). 
Therefore, COX-2 mediated mechanisms may be sig-
nificantly affected by estrogen and thus by gender.
Naproxen is an NSAID commonly used in dental re-
search to manage postoperative pain and swelling, and 
several studies have shown that it effectively manages 
both chronic and acute pain (2,3,8,17). More specifical-
ly, 500 mg of oral naproxen has been extensively stud-
ied in randomized, double-blind, crossover trials dem-
onstrating its efficacy in managing acute pain, swell-
ing and trismus after bilateral extraction of lower third 
molars in similar positions (4,6,17,18). However, since 
this propionic acid derivative is a nonselective inhibitor 
of COX, it is associated with gastrointestinal problems 
such as gastric ulcers, gastrointestinal perforations, and 
stomach bleeding (7) along side its analgesic, antipyret-
ic and anti-inflammatory properties (2,3,7,8,13). In view 
of these gastrointestinal complications, an enteric coat-
ing of esomeprazole magnesium (20 mg) was developed 
in combination with naproxen (500 mg). In particular, 
an oral tablet of naproxen/esomeprazole (NE) comes in 
two dosage strengths, 500/20 mg and 375/20 mg (19).
Briefly, esomeprazole inhibits the H+/K+-ATPase pro-
ton pump, and an enteric coating of esomeprazole over 
naproxen, which is activated by acid should in theory 
reduce the secretion of protons in the stomach. Namely, 
naproxen is delayed in its absorption by approximately 
26 to 72 minutes while the coating of esomeprazole is 
absorbed (19). The reduction of stomach acid by esome-
prazole in essence may then protect the stomach lining 
from gastrointestinal problems associated with COX-1 
inhibition while the plasma concentration of naproxen 
increases (19). Therefore, management of acute pain 
may be delayed with NE compared to naproxen alone, 
yet gastrointestinal problems might be reduced (19). 
However it should be noted that local anesthetics typi-
cally employed during third molar extraction requiring 
osteotomies may last approximately 195 minutes after 
surgery and, thus, the postoperative pain immediately 
after surgery will be maintained by a combination of lo-
cal anesthesia and postoperative pain medication (5).
Thus, the aim of this study was to evaluate the clinical 
efficacy of naproxen (500 mg) versus NE (500/20 mg) 
consumed by volunteers every 12 hours for 4 days after 
undergoing bilateral lower third molar surgery with mo-
lars in similar positions using a double blinded crosso-
ver randomized design.
Med Oral Patol Oral Cir Bucal. 2017 Jan 1;22 (1):e122-31.                                                                         Efficacy of naproxen with or without esomeprazole after bilateral third molar extraction
e124
Material and Methods
- Registration and Study Design
This study was performed in accordance with the Dec-
laration of Helsinki and  approved by the institutional 
Ethics Committee of the Bauru School of Dentistry, 
University of São Paulo, Brazil National Research Eth-
ics System (CAAE number: 30317314.4.0000.5417),  in 
accordance with resolution 466/12 of the National Coun-
cil of Health / Ministry of Health, and registered with 
ClinicalTrials.gov (NCT02494856;https:// clinicaltrials.
gov/show/ NCT02494856). All volunteers completed an 
Informed Consent form during screening prior to car-
rying out any study procedures. Sample size was deter-
mined based on previously published studies (20).
Briefly, 52 adults (≥18 yrs old) requiring bilateral lower 
third molars that were similarly positioned (5,21), ac-
cording to the Pell and Gregory’s classification - clas-
sified by panoramic radiograph (22) were screened for 
participation in this study. Inclusion criteria included a 
lack of inflammation or infection at the extraction sites 
and an absence of systemic diseases that could possi-
bly interfere with the study. Furthermore, extractions 
were based on orthodontic, periodontic and endodontic 
indications, among other dental indications (e.g. caries 
or periodontal pockets in the distal region of the sec-
ond molar), to assess the risk of resorption of the second 
molar root.
Exclusion criteria included the following: history of 
allergy to local anesthetics or any inability to receive 
articaine; history of bleeding or gastrointestinal ulcers, 
kidney disease, asthma, or allergic sensitivity to any 
NSAIDs; individuals pregnant or breast-feeding; use of 
antidepressants within one year before the research; use 
of anticoagulants, diuretics and/or antibiotics within 
two months before surgery; and hepatic, kidney, intes-
tinal, cardiac, pulmonary, circulatory and/or brain dys-
function (5,21). Furthermore volunteers were excluded 
from the study if they had adverse drug reactions (e.g. 
an allergic reaction to any medications) or required dif-
ferent doses of local anesthetic during surgery (23).
- Surgery Intervention and Assessments
Initially, 52 volunteers who fulfilled all the criteria were 
screened based on their panoramic radiographs from the 
Bauru School of Dentistry archives, University of São 
Paulo (Bauru, SP, Brazil). Of these 52 patients, six were 
excluded from the study. Specifically, one volunteer had 
postoperative complications experiencing allergy, an-
other became pregnant before the second surgery and 
the other four volunteers dropped out of the study. In to-
tal, there were 92 extracted third molars (46 volunteers) 
that were analyzed (Fig. 1).
Fig. 1. CONSORT flow diagram of the study design.
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All surgeries were performed by the same dental surgeon 
(GMW) using a standard protocol (5,20,21,24) and 
occurred from June to November 2015 at the Clinical 
Pharmacology and Physiology Laboratory (LAFFIC) 
at Bauru School of  Dentistry, University of São Paulo 
(Bauru, SP, Brazil). All surgical procedures and the drugs 
provided to patients had their costs funded by São Paulo 
Research Foundation (FAPESP) - process number 2013 / 
26467-2. The side (right or left) for the first operation and 
NSAID to be used (naproxen or NE) after this surgery 
were determined randomly (http://www.randomization.
com, number: 27159). Specifically, volunteers received 
either a yellow or brown coded package containing the 
NSAID for consumption after the first surgery, and then 
was given the alternate package for their second surgery 
on the contralateral side (23,24).
Starting immediately after the first surgery, the 
volunteers randomly consumed either one 500 mg tablet 
of naproxen or one tablet with 500 mg of naproxen with 
a 20 mg enteric coating of esomeprazole (NE) every 
12 h for 4 d. Specifically, volunteers consumed the 
research medication during the following times: 0, 12, 
24, 36, 48, 60, 72, 84 and 96h. During the first hour, 
volunteers remained on the research premises and were 
observed while they recorded their postoperative pain 
using a visual analog pain scale (VAS). Volunteers 
were also provided with rescue medication (500 mg 
acetaminophen tablets) that could be consumed every 
8 h to supplement the naproxen or NE medication and 
were instructed explicitly to maintain the use of the 
research medication for the entire protocol. The second 
surgery was performed 4 to 6 weeks after the first 
surgery, where the previous research medication not 
used was then taken.
Postoperative pain was evaluated as described in earlier 
studies (5,21). Briefly, volunteers evaluated postopera-
tive pain using a VAS (0 to 100 mm) with 0 mm indi-
cating no pain and 100 mm indicating worst possible 
pain. Additionally, postoperative pain was recorded by 
the volunteer during the following specific time points 
after surgery: 0, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 
10, 12, 18, 24, 48, 72 and 96 h (the end of surgery was 
considered time zero). Patients also received another 
VAS form without pre-determined times to record the 
amount of pain experienced at the time when rescue 
medication was consumed. In addition to the forms re-
corded by the volunteers, a single researcher (GMW) 
evaluated the following parameters in the pre, intra 
and postoperative periods. Antibiotics were prescribed 
to volunteers only in cases where local oral infections 
were observed during follow-up visits.
- Collected data and surgical outcomes
All the parameters evaluated in this study are reported 
in table 1.
- Statistical Analysis
Data were analyzed using Microsoft® Excel 2002 (ver-
sion 10.6871.6870) and IBM®SPSS® statistics (version 
20.0.0). Briefly, data were tested for normality using 
the Shapiro-Wilk test. When data were normally dis-
tributed, comparisons between the naproxen and NE 
groups were made using paired Student’s t-tests, and 
in cases where data were non-normally distributed, the 
Mann-Whitney U test was employed. The chi-square 
goodness of fit test was used to compare observed ratios 
with expected ratios (e.g. observed versus expected ra-
tio of females to males). Lastly, binary data such as the 
absence or presence of an adverse reaction (e.g. head-
ache) between naproxen and NE or female and male 
were compared using Fisher’s exact test. Statistical sig-
nificance was set at 0.05. Normally distributed data are 
reported as a mean ± 1 standard deviation (SD) whereas 
non-normally distributed data are reported as median 
with the interquartile range [IQR].
Results
A total of 46 volunteers (92 molars) were studied of 
which 34 (74%) were female aged 25 ± 6 yrs and 12 (26 
%) were male aged 28 ± 7 yrs (Table 2). The average age 
of all the patients was 26 yrs, with ages ranging from 18 
to 44 yrs. For unknown reasons, the observed ratio of 
female to males (17:6) was significantly different from 
the expected ratio of female to males (50.43:49.57) in 
the age range tested (chi-square goodness of fit test, p< 
0.001). Consequently, the naproxen and NE groups were 
investigated in total and separated by gender resulting 
in several significant findings.
While nine women compared to no men reported ad-
verse reactions this observed difference was not statisti-
cally different (Fisher’s exact test, p = 0.105). Adverse 
reactions reported by women were not significantly 
different when they consumed naproxen compared to 
NE (Fisher’s exact test, p = 0.476). When consuming 
naproxen, 2 women reported headaches while a third re-
ported nausea and diarrhea. Similarly, when consuming 
NE, 3 women reported headaches, 1 woman reported 
stomachaches, and 2 women reported vomiting with 
one of those women also reporting nausea. Lastly, on 
the 7th day after surgery, two women in the NE group 
had developed infections at the site of surgery and were 
prescribed 500 mg of amoxicillin for 8 hours for 7 days; 
these two patients were followed until their infection 
was resolved.
The time duration between the end of surgery and when 
female volunteers first consumed rescue medication to 
supplement their experimental pain medication was 
significantly increased when they consumed naproxen 
when compared to consuming NE (6.7 h [0.5] versus 3.7 
h [3.3], respectively; Mann-Whitney U test, p= 0.03) as 
reported in table 2.
As indicated by the VAS (Fig. 2A), reported postopera-
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tive pain scores were no different between men when 
they consumed naproxen and NE. However, reported 
postoperative pain scores were significantly increased 
between women when they consumed naproxen com-
pared to NE at time points 1, 1.5, 2, 3, and 4 h after 
surgery (Fig. 2B). Women who consumed naproxen 
alone reported significantly less postoperative pain at 
0.5, 0.75, 1.0, 1.5 and 2.0 h after surgery when compared 
to men who consumed naproxen alone (Mann-Whitney 
U test, p < 0.05) as reported in fig. 2C.
All other parameters tested whether preoperative, intra-
operative or postoperative were not found to be signifi-
cantly different between men and women or between 
both genders combined when consuming naproxen or 
NE (Table 2, Fig. 3). For example, mouth opening or 
indicators of inflammation such as swelling were no 
different between females or males who consumed 
naproxen when compared NE consumption. Specifical-
ly, increased facial swelling of men and women on the 
2nd postoperative day had measurements of 105.9± 3.4% 
and 106.5± 7.6% respectively, when taking naproxen, 
compared to 104.7± 2.7% and 105.4± 3.2% respectively 
when taking NE (Table 2). Similarly, on the 7th post-
operative day, increased facial swelling of men and 
women had measurements of 101.9 ± 2.2% and 103.3± 
7.8% respectively, when taking naproxen, compared to 
100.7± 1.2% and 101.8± 1.7% respectively when taking 
NE (Table 2).
Discussion
To the best of the authors’ knowledge, this study is the 
first to investigate the clinical efficacy of naproxen ver-
sus naproxen with an enteric coating of esomeprazole 
(NE) using a model of acute pain immediately after 
surgery, followed by lower pain intensity measurements 
up to 96 hours after surgeries. Briefly, a double-blinded 
crossover randomized study design has the advantage 
of comparing two drugs with the same population of 
Parameter Unit
Total volume of local anesthetic mL
Onset of anesthetic agent action min
Surgery duration min
Overall experience of surgery reported by volunteer
5-point scale: 1) “poor”; 2) “fair”; 3) “good”; 4) “very good”; 
5) “excellent” 
Quality of anesthesia
3-point scale: 1) no discomfort during surgery; 2) any dis-
comfort without anesthesia required; 3) any discomfort with 
anesthesia required
Surgery difficulty
3-point scale: 1) no need for osteotomies without tooth sec-
tioning; 2) need for osteotomies without tooth sectioning; 3) 
need for osteotomies and tooth sectioning complicated
Intraoperative bleeding
3-point scale: 1) minimal bleeding; 2) normal bleeding; 3) 
excessive bleeding
Quality of wound healing
7th day; 3-point scale: 1) normal healing without inflamma-
tion; 2) delayed healing; 3) healing complicated by inflam-
mation or local infection with or without purulent material
Adverse reactions
Observed by the surgeon or reported by the volunteer, during 
the surgery in the first postoperative hour and during the 2nd 
and 7th days after surgery
Systolic, diastolic, and mean arterial pressure; heart rate 
and oxygen saturation*
mmHg; bpm and % SpO2
Body temperature Preoperative period, 2nd, 7th postoperative day  (oC) 
Mouth opening Preoperative period, 2nd, 7th postoperative day (mm) 
Facial swelling Preoperative period, 2nd, 7th postoperative day (mm) 
Subjective evaluation of postoperative pain Visual analog scale (VAS, 0 to 100 mm)
Total amount of rescue medication Number of tablets
Table 1. Study parameters evaluated.
* Dixtal® (model DX2021, Dixtal Biomédica Ind and Com Ltda, Marília, SP, ANVISA/MS 10293490035, model number 101503732).
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individuals, hopefully minimizing confounding factors 
introduced by comparing two populations. To ensure 
the integrity of the results of this crossover study all 
the volunteers were selected based on the bilateral po-
sitioning of their teeth with each volunteer’s molars in 
similar positions minimizing differences in the surgical 
trauma between both surgeries (20,23,24,25). In deed, 
each group tested had similar interoperative parameters 
(including hemodynamic parameters – data not shown) 
during surgery (Table 2).
The manufacturer of NE (AstraZeneca; London, United 
Kingdoms) explicitly indicates the use of NE for chron-
ic and not acute pain stating that “VIMOVO is not rec-
ommended for initial treatment of acute pain because 
the absorption of naproxen is delayed compared other 
naproxen-containing products”. However, according 
to the manufacture, “esomeprazole is rapidly absorbed 
with peak plasma concentration reached within, on av-
erage, 0.43 to 1.2 hours” (19) and chronic pain is clini-
cally described as pain lasting beyond 3 or 6 months. 
Thus it is assumed that a dose of NE could be effective 
for pain lasting several days or hours i.e. acute pain. 
Similarly, naproxen has been reported to have a peak 
plasma concentration within about 1 hour (7,19).
Indeed NE was found to be effective in managing pain 
several hours after surgery when acute anesthesia wore 
off. Without any pain management, patients would re-
port extremely grievous pains scores. Compared to 
other pain medications such as nimesulide, ketoprofen, 
ibuprofen and piroxicam, which are indicated for the 
treatment of acute pain and chronic pain, both naproxen 
and NE had comparable pain scores. Therefore, despite 
the indication by the manufacturer for the exclusive 
control of chronic pain by NE, this study found that NE 
 All (n = 92) 
Females with 
Naproxen 
(n = 34) 
Females with 
NE (n = 34) 
Males with 
Naproxen 
(n = 12) 
Males with NE  
 (n = 12) 
Age (mean years. SD) 26 (6) 25 (6) 25 (6) 28 (7) 28 (7) 
 
Lower third molar position (Pell & Gregory Classification; n. %) 
     IA 30 33% 10 29% 9 26% 5 42% 6 50% 
     IB 6 7% 2 6% 4 12% 0 0% 0 0% 
     IC 0 0% 0 0% 0 0% 0 0% 0 0% 
     IIA 30 33% 11 32% 11 32% 5 42% 3 25% 
     IIB 18 20% 8 24% 7 21% 1 8% 2 17% 
     IIC 7 8% 2 6% 3 9% 1 8% 1 8% 
     IIIA 1 1% 1 3% 0 0% 0 0% 0 0% 
     IIIB 0 0% 0 0% 0 0% 0 0% 0 0% 
     IIIC 0 0% 0 0% 0 0% 0 0% 0 0% 
Surgery (median. IQR)  
     duration (minutes) 22.5 9.0 21.5 5.8 23.0 9.0 22.0 11.3 24.5 9.3 
     difficulty (score assessed by surgeon) 3.0 1.0 3.0 1.0 2.0 1.0 2.5 1.0 3.0 0.3 
     intraoperative bleeding (score assessed by 
surgeon) 1.0 0.1 1.0 0.1 1.0 0.0 1.1 0.2 1.0 0.0 
     quality of wound healing (score assessed by 
surgeon) 1.0 0.0 1.0 0.0 1.0 0.0 1.0 0.0 1.0 0.0 
     quality of surgery (score assessed by volunteer) 2.0 1.0 2.0 1.0 2.1 0.9 1.8 0.8 1.8 1.0 
Local anesthetic.  (median. IQR)  
     quantity (mL) 3.6 0.9 3.6 0.9 3.6 0.9 3.6 1.1 3.6 0.9 
     onset (seconds) 91 65 90 48 98 75 85 65 90 54 
     quality (score assessed by surgeon) 2.0 2.0 2.0 1.5 2.0 1.0 2.0 1.0 2.0 1.3 
Mouth Opening  (median mm. IQR)           
     preoperative measurement  50 8 45 10 45 8 50 11 53 5 
     2 day postoperative measurement  25 10 20 5 20 9 30 6 33 10 
     7 day postoperative measurement  35 18 35 15 30 15 41 6 43 15 
Facial Swelling (mean mm. SD)  
     preoperative measurement  370 31 360 20 363 23 400 15 393 15 
     2 day postoperative measurement  390 30 380 24 383 19 418 18 410 8 
     7 day postoperative measurement  375 31 365 15 373 19 405 8 400 18 
Under-arm temperature  (median oC. IQR)  
     preoperative measurement 36.0 0.8 35.9 0.9 36.1 0.7 36.1 0.6 36.2 1.0 
     2 day postoperative measurement 35.9 0.7 36.0 1.1 35.9 0.7 36.0 0.5 35.9 0.6 
     7 day postoperative measurement 36.0 0.8 35.9 0.8 36.0 1.0 36.2 0.5 36.1 0.8 
Paracetamol rescue medication (median. IQR)  
     time between first consumption & surgery (hr) 5.9 3.7 6.7 0.5 3.7* 3.3 5.7 2.7 3.2 2.5 
     VAS during first consumption (mm) 31 33 28 28 36 20 52 45 19 57 
     total quantity consumed (mg) 1500 2250 2250 3750 1500 1875 750 0 740 563 
!
Table 2. Preoperative, intraoperative and postoperative parameters.
* significantly different from the same parameter versus naproxen (Mann-Whitney U test. p-value < 0.05).
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was effective against acute postoperative pain, with al-
most all postoperative pain scores reported well below 
40 mm at all time points.
It should be noted that patients consumed their first dose 
of naproxen or NE immediately after surgery, and that 
the local anesthetic used (4% articaine with 1:200,000 
epinephrine) has been demonstrated to last on average 
193 minutes according Gregorio et al. (20) (2008) or 196 
minutes according Santos et al. (24) (2007) after admin-
istration during third molar surgeries with osteotomies. 
Thus, postoperative pain between 0 and approximately 
3.3 hours is most likely managed by the local anesthe-
sia while approximately between 40 minutes and 3.3 
hours postoperative pain is probably being managed by 
a combination of local anesthesia, which is waning and 
the oral medication which is waxing. Therefore, even 
with the delayed absorption of NE reported by the man-
ufacturer, the volunteers in this study never reported 
significant amounts of acute postoperative pain during 
any time point tested after surgery.
Jensen et al. (26) (2005) found that patients who had 
postoperative pain experiences or chronic pain with pain 
intensity levels of ~44 mm on a 100 mm VAS tend to de-
scribe their pain as “soft” and reported that this level of 
pain minimally impacts their daily activities. Overall, the 
reported pain score for all groups were on average well be-
low 40 mm on the VAS throughout the entire study, which 
is considered low clinically; furthermore adverse reactions 
were minimal. Therefore, both medications should be con-
sidered effective for managing postoperative pain.
Other studies have demonstrated the clinical efficacy of 
different formulations (250, 400 and 500 mg) of naprox-
Fig. 2. Postoperative Pain Scores with Naproxen (500 mg) or Naproxen with Esomeprazole (NE, 500/20 mg) in Volunteers. Visual analog 
scale (VAS) of self-reported postoperative pain scores after lower third molar surgeries assessed at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 
10, 12, 18, 24, 48, 72 and 96 h. Scores could range from 0 to 100 mm with larger scores indicating increased pain. Data are presented as 
median and IQR (n = 46). * indicates a significant difference from naproxen, Mann-Whitney U test, p-value ≤ 0.05. t indicates a significant 
difference from women in the same group, Mann-Whitney U test, p-value ≤ 0.05.
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en to combat edema and pain trismus using a third mo-
lar surgery model (1-3,6,8,17,18). These formulations of 
naproxen in their different therapeutic doses reportedly 
manage postoperative pain and inflammation effective-
ly (1,2-4,8,17,18).
Despite naproxen’s demonstrated effectiveness against 
inflammation and pain, it has been associated with gas-
trointestinal problems when used for long periods and/
or at high doses (7,17,27). However, in this study adverse 
reactions from naproxen were minimal, and the presence 
of esomeprazole did not significantly reduce the number 
of adverse reactions to naproxen in the population of vol-
unteers studied (NE versus naproxen). Specifically, the 
number of adverse reactions experienced in all groups 
was quite low and, in particular, men reported no adverse 
reactions at any time with either medication.
Other studies have found varying degrees of adverse re-
actions when taking naproxen after third molar surgery. 
For example, Varner et al. (6) (2009) found adverse 
side effects in patients (aged 22 ± 5 yrs) who consumed 
naproxen (550 mg) with 8 (16%) patients reporting nau-
sea, 8 (16%) reporting headache, 4 (8%) reporting diz-
ziness, 4 (8%) reporting vomiting and 3 (6%) diagnosed 
with dry socket. Whereas, Michael Hill et al. (8) (2006) 
reported that 14 out of 39 (36%) individuals (aged 25 ± 4 
yrs) experienced at least one adverse reaction when they 
consumed naproxen (500 mg) with the most common 
adverse side effects being alveolitis, headaches, gingi-
vitis, and dizziness.
NSAIDs have been shown to adversely affect older 
populations when compared to younger populations. 
However, there were no significant differences between 
Fig. 3. Global Evaluation of Overall Experience. Self-reported global efficacy of oral naproxen (500 
mg) compared to naproxen with esomeprazole (NE, 500/20 mg). during the seventh postoperative 
day as assessed using a 5-level Likert scale (n = 46). The format of the Likert ratings was “excel-
lent,” “very good,” “good,” “fair,” or “poor”. * Indicates a p-value ≤ 0.05, Mann-Whitney U test for 
the “excellent” sub-group between research medications.
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the ages of women and men in this study, and therefore 
should not have been a factor in the adverse reactions to 
NSAIDs observed in this study.
Curiously, results from this study also suggest that naprox-
en alone manages acute postoperative pain in women more 
effectively when compared to NE, and that postoperative 
pain in men would be effectively managed by either medi-
cation. For the women examined in this investigation, the 
delay in the absorption of naproxen after the coating of 
esomeprazole was digested might have resulted in more 
postoperative pain immediately after surgery when the lo-
cal anesthetic dissipated. In contrast, men did not experi-
ence a difference in postoperative pain between the two re-
search medications, and it remains unclear why men were 
different from women in this respect.
Keep in mind, when women consumed NE they also on 
average consumed their first rescue medication (aceta-
minophen) much earlier then when they consumed 
naproxen without esomeprazole (3.7 h versus 6.7 h, re-
spectively). Therefore, not only were women reporting 
more postoperative pain when taking NE when com-
pared to naproxen, but they also consumed supplemental 
pain medication at a much earlier time after surgery.
It is unclear whether other studies have observed any 
gender differences for postoperative pain when using 
naproxen (or NSAIDs in general). Perhaps this study is 
the first to find a difference in postoperative pain be-
tween men and women when consuming naproxen.
Estrogen is also associated with increased circulating 
prostaglandins and prostacyclin in human and other 
animal experiments (15). According Amandusson & 
Blomqvist (10) (2013), when compared to men, women 
have increased pain somatization, sensitivity and intoler-
ance for various types of pain. The authors reported that 
the presence of estrogen in women favors nerve trans-
mission in spinal nociceptive circuits and supraspinal 
levels in the central nervous system, thus contributing to 
pain transmission and modulation. This may help explain 
increased pain sensitivity observed in women in this and 
other studies. Additionally, Cherney et al. (13) (2008) 
found that women were significantly sensitive to COX-2 
inhibition whereas men were not. They hypothesized that 
women have greater baseline prostaglandin activity when 
compared to men and that vasodilatory prostaglandins are 
more effective in women versus men (13). Others using 
animal models have reported or implicated estrogen as a 
mediating factor, since estrogen increased vasodilatory 
prostaglandin synthesis (14-16). Taken together, COX-2 
mediated mechanisms may be significantly affected by 
estrogen and thus by gender. Whether men reported 
more postoperative pain than women when consuming 
naproxen alone in the first two hours after surgery, due to 
the effects of estrogen or other sex hormones on COX-2, 
requires further investigation.
Currently, there are still no other randomized clinical 
trials evaluating the effectiveness of NE using an acute 
pain control model (22). NE has only been evaluated 
for its ability to manage chronic pain (19,28). However, 
its efficacy, tolerability and bioavailability have been 
widely tested by Choi et al. (27) (2015) and Angiolillo 
et al. (28) (2014).
Indirect and direct parameters investigating postopera-
tive inflammation (e.g. mouth opening and swelling) indi-
cate that naproxen and NE equally manage postoperative 
inflammation often associated with invasive oral surgery. 
In particular, the reduction of the mouth opening, known 
as trismus, during the postoperative period is reported 
by several authors, and it is closely linked to the level of 
swelling and inflammation generated by surgery. Lim-
ited mouth opening is typically associated with moderate 
inflammation; although it is sometimes associated with 
more severe trismus (29). With respect to mouth open-
ing, this study found no significant differences between 
the naproxen and NE groups (in both genders) suggest-
ing that medications are equally effective in combating 
postoperative trismus, a result which agrees with other 
studies from this laboratory (5,20,21,23,24,25). By the 
7th postoperative day volunteers were able to open their 
mouth nearly equal to preoperative distances.
Swelling is an expected reaction after third molar ex-
tractions, with swelling being the greatest 48 hours 
after surgery (21). This study found no differences in 
swelling between volunteers when they consumed 
naproxen alone or with esomeprazole. There are sev-
eral studies that have investigated the effectiveness of 
NSAIDs on inflammation originating from third molar 
surgeries (1-3,5,6,9). For example, Bjornsson et al. (17) 
(2003) reported that naproxen (500 mg twice daily for 
3 d) reduced swelling 20.9% on the 6th day after third 
molar surgery although acetaminophen (1000 mg four 
times daily for 3 d) was more effective. In contrast, Ak-
bulut et al. (1) (2014) found that naproxen was less ef-
fective against swelling when compared to diclofenac 
potassium. Additionally, Kara et al. (2) (2010) reported 
that naproxen sodium ineffectively reduced swelling in 
patients, being equivalent to placebo.
In conclusion, both naproxen (500 mg) and NE (500/20 
mg) effectively manage postoperative pain and inflam-
mation in adults after third molar surgery with pain 
scores rarely exceeding more than mild pain. However, 
in terms of postoperative pain, women benefited more 
when consuming naproxen alone then with esomepra-
zole, whereas men were no different between the two 
medications. Additionally, adverse side effects were 
minimal in volunteers and no significant differences 
were found between volunteers when they consumed 
naproxen or NE.
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